CIBICI   14215
CENTRO DE INVESTIGACION EN BIOQUIMICA CLINICA E INMUNOLOGIA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
BENZNIDAZOLE-LOADED MULTIPARTICULATE DRUG DELIVERY SYSTEMS IMPROVE EXPERIMENTAL CHAGAS DISEASE PHARMACOTHERAPY
Autor/es:
MONICA CRISTINA GARCIA; NICOLÁS ERIC PONCE; LILIANA MARIA SANMARCO; MARIA DEL PILAR AOKI; NATALIA EBERHARDT; ALVARO JIMENEZ KAIRUZ
Lugar:
Buenos Aires
Reunión:
Congreso; I Reunión de Biociencias; 2017
Institución organizadora:
Sociedad Argentina de Protozoologia
Resumen:
Benznidazole (BZ) is the selected drug for Chagas disease treatment, showing a parasitological cure rate of 60-80% during the acute phase. High frequency of administration, long-term treatment, andseveral side effects are issues that negatively affect therapeutic success. We have developed BZ-loaded multiparticulate drug deliverysystems (MDDS) that showed modifed release of BZ. These pharmaceutical strategies would reduce side effects of BZ and/or allowreducing its frequency of administration. The present work aimed toevaluate the effcacy and safety of BZ-loaded MDDS compared tothe reference treatment (BZ 100 mg/kg daily) in a murine model ofChagas disease. BALB/c mice were ip infected with 1000 Tulahuentrypomastigotes, and after 15 days post-infection (dpi) were orallytreated with BZ-loaded MDDS or pure BZ at 50 and 100 mg/kg dailyor intermittent (2 or 5 day intervals). In order to accurately assesseffcacy, at 105 dpi mice were immunosuppressed with 4 doses ofcyclophosphamide at 3 day intervals. Then, mice were sacrifcedand parasitemia, parasite heart-load, relative weight of spleens, livers and hearts, and tissue injury biomarkers were analyzed. Treated animals presented a survival higher than 80% compared tomice infected and non-treated (INT) which showed a survival of 9%(p